United Kingdom · Question · Written question
UIN 96071
Abiraterone
Original
Introduced
1 December 2025
Last action
2 February 2026 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
2 February 2026
Summary
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 28 October 2025 to Question 83204, what step he is taking to secure a recurrent budget for abiraterone in high risk, non-metastatic prostate cancer, in the context of it b
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
1 December 2025
Written question
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 28 October 2025 to Question 83204, what step he is taking to secure a recurrent budget for abiraterone in high risk, non-metastatic prostate cancer, in the context of it b
Source: Commons
2 February 2026
Answer
We are pleased to confirm that NHS England announced on 16 January that patients with non‑metastatic prostate cancer will now have access to abiraterone in combination with prednisolone, where it is deemed to be clinically beneficial. This development has...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2025-12-01/96071
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1859002
- uk · wq-1859002 · source updated 2 February 2026